Daniel Rabinowitz Sells 787 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Daniel Rabinowitz sold 787 shares of the stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total value of $71,916.06. Following the completion of the transaction, the insider now owns 205,552 shares of the company’s stock, valued at approximately $18,783,341.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Daniel Rabinowitz also recently made the following trade(s):

• On Thursday, February 29th, Daniel Rabinowitz sold 20,526 shares of Natera stock. The shares were sold at an average price of $89.01, for a total value of $1,827,019.26.
• On Tuesday, February 27th, Daniel Rabinowitz sold 35,307 shares of Natera stock. The shares were sold at an average price of $75.09, for a total value of $2,651,202.63.

Natera Price Performance

Shares of NASDAQ NTRA opened at $91.50 on Thursday. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $11.05 billion, a price-to-earnings ratio of -24.29 and a beta of 1.37. The business has a 50 day simple moving average of $86.85 and a 200-day simple moving average of $66.82.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. The business had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. As a group, equities research analysts expect that Natera, Inc. will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Simplicity Wealth LLC bought a new position in Natera during the 1st quarter worth $223,000. Fifth Third Bancorp lifted its holdings in shares of Natera by 3.5% in the first quarter. Fifth Third Bancorp now owns 6,432 shares of the medical research company’s stock valued at $588,000 after buying an additional 216 shares during the period. Arcadia Investment Management Corp MI lifted its holdings in shares of Natera by 47.8% in the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock valued at $49,000 after buying an additional 174 shares during the period. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Natera in the first quarter valued at $2,606,000. Finally, Maryland State Retirement & Pension System lifted its holdings in shares of Natera by 11.2% during the first quarter. Maryland State Retirement & Pension System now owns 8,535 shares of the medical research company’s stock valued at $761,000 after purchasing an additional 857 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several research reports. Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a report on Friday, April 5th. The Goldman Sachs Group lifted their price objective on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. Raymond James cut Natera from a “strong-buy” rating to an “outperform” rating and lifted their price objective for the stock from $68.00 to $85.00 in a research report on Tuesday, February 20th. Craig Hallum started coverage on Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 price objective for the company. Finally, BTIG Research lifted their price objective on Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, December 29th. One investment analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.